PL3536339T3 - Sposoby poprawy objawów astmy przy zastosowaniu benralizumabu - Google Patents

Sposoby poprawy objawów astmy przy zastosowaniu benralizumabu

Info

Publication number
PL3536339T3
PL3536339T3 PL19162585T PL19162585T PL3536339T3 PL 3536339 T3 PL3536339 T3 PL 3536339T3 PL 19162585 T PL19162585 T PL 19162585T PL 19162585 T PL19162585 T PL 19162585T PL 3536339 T3 PL3536339 T3 PL 3536339T3
Authority
PL
Poland
Prior art keywords
benralizumab
methods
asthma symptoms
improving asthma
improving
Prior art date
Application number
PL19162585T
Other languages
English (en)
Inventor
Christine Ward
Lorin Roskos
Bing Wang
Donald Raible
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PL3536339T3 publication Critical patent/PL3536339T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL19162585T 2013-08-12 2014-08-07 Sposoby poprawy objawów astmy przy zastosowaniu benralizumabu PL3536339T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361864950P 2013-08-12 2013-08-12
EP14836392.2A EP3033103B1 (en) 2013-08-12 2014-08-07 Methods for improving asthma symptoms using benralizumab
PCT/US2014/050122 WO2015023508A2 (en) 2013-08-12 2014-08-07 Methods for improving asthma symptoms using benralizumab
EP19162585.4A EP3536339B1 (en) 2013-08-12 2014-08-07 Methods for improving asthma symptoms using benralizumab

Publications (1)

Publication Number Publication Date
PL3536339T3 true PL3536339T3 (pl) 2022-02-21

Family

ID=52448839

Family Applications (2)

Application Number Title Priority Date Filing Date
PL19162585T PL3536339T3 (pl) 2013-08-12 2014-08-07 Sposoby poprawy objawów astmy przy zastosowaniu benralizumabu
PL14836392T PL3033103T3 (pl) 2013-08-12 2014-08-07 Sposoby poprawy objawów astmy przy zastosowaniu benralizumabu

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL14836392T PL3033103T3 (pl) 2013-08-12 2014-08-07 Sposoby poprawy objawów astmy przy zastosowaniu benralizumabu

Country Status (18)

Country Link
US (1) US9441047B2 (pl)
EP (3) EP3536339B1 (pl)
JP (2) JP6803229B2 (pl)
KR (1) KR102337601B1 (pl)
CN (2) CN111617244A (pl)
AU (3) AU2014306960B2 (pl)
BR (1) BR112016002462A8 (pl)
CA (1) CA2918050C (pl)
DK (2) DK3536339T3 (pl)
ES (2) ES2740355T3 (pl)
HK (2) HK1221647A1 (pl)
HU (2) HUE045402T2 (pl)
MX (1) MX368474B (pl)
PL (2) PL3536339T3 (pl)
RU (2) RU2728578C2 (pl)
SG (1) SG11201600484TA (pl)
TR (1) TR201910413T4 (pl)
WO (1) WO2015023508A2 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2866426T3 (es) 2013-08-12 2021-10-19 Astrazeneca Ab Métodos para incrementar el volumen espiratorio forzado en pacientes asmáticos que usan benralizumab
CA2918105C (en) 2013-08-12 2023-02-28 Medimmune, Llc Methods for reducing exacerbation rates of asthma using benralizumab
CN105636607A (zh) * 2013-10-15 2016-06-01 免疫医疗有限责任公司 用于使用贝那利珠单抗治疗慢性阻塞性肺疾病的方法
WO2017077391A2 (en) 2015-11-04 2017-05-11 Astrazeneca Ab Dipeptidyl peptidase-4 and periostin as predictors of clinical response to eosinophil-targeted therapeutic agents in eosinophilic diseases
US20180056018A1 (en) * 2016-08-31 2018-03-01 Cephalon, Inc. Inhalation Systems, Devices and Methods
TW202214692A (zh) * 2020-06-05 2022-04-16 瑞典商阿斯特捷利康公司 治療患有鼻瘜肉的患者的重度氣喘之方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU690474B2 (en) 1995-09-11 1998-04-23 Kyowa Hakko Kirin Co., Ltd. Antibody againts alpha-chain of human interleukin 5 receptor
US6746839B1 (en) * 1998-01-12 2004-06-08 Interleukin Genetics, Inc. Diagnostics and therapeutics for an obstructive airway disease
ES2571230T3 (es) 1999-04-09 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedimiento para controlar la actividad de una molécula inmunofuncional
CA2402477A1 (en) 2000-02-15 2001-08-23 Kyowa Hakko Kogyo Co., Ltd. Eosinophil-specific apoptosis inducer
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
EP1688437A4 (en) 2003-10-08 2007-09-26 Kyowa Hakko Kogyo Kk SPECIALLY BINDING ANTIBODY COMPOSITION TO IL-5 RECEPTOR
US20060014680A1 (en) 2004-07-13 2006-01-19 Caiding Xu Peptides and compounds that bind to the IL-5 receptor
AU2006299429B2 (en) 2005-10-03 2012-02-23 Xencor, Inc. Fc variants with optimized Fc receptor binding properties
NO3072525T3 (pl) 2007-05-14 2018-06-30
EP3447491A3 (en) 2010-12-16 2019-06-05 F. Hoffmann-La Roche AG Diagnosis and treatments relating to th2 inhibition
US8961965B2 (en) * 2011-05-18 2015-02-24 Medimmune, Llc Methods of diagnosing and treating pulmonary diseases or disorders
MX2014004968A (es) 2011-11-01 2014-08-01 Medimmune Llc Metodos para reducir la frecuencia y la gravedad de exacerbaciones agudas de asma.
ES2866426T3 (es) 2013-08-12 2021-10-19 Astrazeneca Ab Métodos para incrementar el volumen espiratorio forzado en pacientes asmáticos que usan benralizumab
CA2918105C (en) * 2013-08-12 2023-02-28 Medimmune, Llc Methods for reducing exacerbation rates of asthma using benralizumab

Also Published As

Publication number Publication date
HK1225303A1 (zh) 2017-09-08
CA2918050A1 (en) 2015-02-19
EP3033103B1 (en) 2019-06-05
PL3033103T3 (pl) 2019-10-31
MX368474B (es) 2019-10-04
JP2016527326A (ja) 2016-09-08
HK1221647A1 (zh) 2017-06-09
AU2014306960A1 (en) 2016-02-04
CN105451761A (zh) 2016-03-30
RU2020123894A (ru) 2020-09-18
CN111617244A (zh) 2020-09-04
RU2016108734A3 (pl) 2018-06-18
CA2918050C (en) 2023-10-03
MX2016001195A (es) 2016-07-21
WO2015023508A2 (en) 2015-02-19
WO2015023508A8 (en) 2015-10-15
RU2728578C2 (ru) 2020-07-30
SG11201600484TA (en) 2016-02-26
EP3988114A1 (en) 2022-04-27
EP3536339B1 (en) 2021-10-06
AU2023214323A1 (en) 2023-10-19
US20150044204A1 (en) 2015-02-12
TR201910413T4 (tr) 2019-08-21
ES2901634T3 (es) 2022-03-23
BR112016002462A2 (pt) 2017-09-12
EP3033103A4 (en) 2017-03-22
WO2015023508A3 (en) 2015-04-16
KR20160042123A (ko) 2016-04-18
EP3536339A1 (en) 2019-09-11
HUE057065T2 (hu) 2022-04-28
RU2016108734A (ru) 2017-09-19
JP2020100653A (ja) 2020-07-02
JP6803229B2 (ja) 2020-12-23
AU2020202564A1 (en) 2020-05-07
HUE045402T2 (hu) 2019-12-30
US9441047B2 (en) 2016-09-13
EP3033103A2 (en) 2016-06-22
BR112016002462A8 (pt) 2018-06-12
KR102337601B1 (ko) 2021-12-10
DK3033103T3 (da) 2019-08-05
AU2014306960B2 (en) 2020-01-16
DK3536339T3 (da) 2021-12-20
ES2740355T3 (es) 2020-02-05

Similar Documents

Publication Publication Date Title
HK1250690A1 (zh) 方法
HK1208363A1 (en) New methods
HRP20190405T1 (hr) Postupci za smanjenje brzine pogoršanja astme korištenjem benralizumaba
PL3019577T3 (pl) Sposób wytwarzania węglowodorów
HK1225303A1 (zh) 使用貝那利珠單抗改善哮喘症狀的方法
EP2925877A4 (en) milling
EP2925876A4 (en) milling
GB201700075D0 (en) Methods to reduce gas carry-uder for cyclonic seperators
GB2507760B (en) Methods
GB201219816D0 (en) Improving local context search results
GB201208874D0 (en) Methods
EP2925790A4 (en) milling
EP2946008A4 (en) METHODS OF MOBILIZING HEMATOPOIETIC STEM CELLS
GB201204280D0 (en) Methods
EP2964773A4 (en) milling
EP2872212A4 (en) METHOD FOR IMPROVING MALE FRUITNESS
GB201316651D0 (en) Asthma
GB201208756D0 (en) Methods
IL236547A0 (en) Methods to improve male fertility
GB201220686D0 (en) Methods
AP2012000550S (en) E-horn methods
GB201216074D0 (en) Methods
GB201208875D0 (en) Methods
GB201208963D0 (en) Methods
GB201207793D0 (en) Methods